Hot Pursuit     01-Apr-24
Biocon gains after receiving MHRA UK approval for Liraglutide injection
Biocon rose 1.17% to Rs 267.20 after the company has received an approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K., for its complex formulation Liraglutide (gSaxenda).
The said approval has received through its European partner, Zentiva.

Liraglutide (gSaxenda) (6mg/ml solution for injection in pre-filled pen), used in the treatment of weight management as an adjunct to a reduced-calorie diet and increased physical activity.

Earlier, the company has received approval from MHRA for Liraglutide (gVicotza), used in the treatment of Type 2 Diabetes Mellitus, filed through Zentiva.

Biocon is an innovation led global biopharmaceuticals company, engaged in the production of therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development.

The company had reported consolidated net profit of Rs 660 crore in Q3 FY24 as compared with net loss of Rs 41.8 crore posted in Q3 FY23. Revenue from operations jumped 34.43% year on year (YoY) to Rs 3,953.7 crore in the quarter ended 31 December 2023.

Previous News
  Biocon consolidated net profit declines 56.74% in the March 2024 quarter
 ( Results - Announcements 16-May-24   18:25 )
  Biocon Ltd eases for fifth straight session
 ( Hot Pursuit - 25-Oct-23   13:35 )
  Biocon's subsidiary receives UK’s MHRA approval for Aflibercept biosimilar
 ( Hot Pursuit - 13-Nov-23   17:05 )
  Biocon Biologics receives UDFDA approval for Yesafili™
 ( Corporate News - 21-May-24   09:13 )
  Biocon to hold board meeting
 ( Corporate News - 11-Apr-24   16:18 )
  Eris Lifesciences avails term loan of Rs 280 cr from Citi Bank
 ( Corporate News - 09-Nov-23   09:15 )
  Biocon PAT slides 57% to Rs 136 crore in Q4 FY24
 ( Hot Pursuit - 17-May-24   10:37 )
  Biocon to declare Quarterly Result
 ( Corporate News - 10-Oct-23   11:29 )
  Biocon to announce Quarterly Result
 ( Corporate News - 07-Jan-23   10:06 )
  Biocon to announce Quarterly Result
 ( Corporate News - 21-Oct-22   10:19 )
  Biocon's biologics arm concludes multi-billion-dollar acquisition of Viatris' biosimilars business
 ( Hot Pursuit - 30-Nov-22   11:47 )
Other Stories
  JSW Energy PAT soars 80% YoY to Rs 522 crore in Q1 FY25
  20-Jul-24   17:15
  Yes Bank Q1 PAT climbs 47% YoY to Rs 502 crore
  20-Jul-24   16:46
  Patanjali Foods Q1 PAT soars 3-fold to Rs 263 cr
  20-Jul-24   16:08
  Nippon Life Q1 PAT surges 40% YoY to Rs 332 cr
  20-Jul-24   15:44
  HDFC Bank Q1 PAT grows 35% YoY to Rs 16,175 crore
  20-Jul-24   15:31
  Kotak Mahindra Bank Q1 PAT zooms 81% YoY to Rs 6,250 cr
  20-Jul-24   15:13
  JSW Steel Q1 PAT drops 64% YoY to Rs 867 crore
  20-Jul-24   13:39
  ICICI Lombard Q1 PAT climbs 49% YoY to Rs 580 cr
  20-Jul-24   12:14
  Oberoi Realty Q1 PAT soars 82% YoY to Rs 584 cr
  20-Jul-24   11:16
  RIL PAT slides 4% YoY to Rs 17,448 crore in Q1 FY25
  20-Jul-24   10:33
Back Top